An observational study in Relapsed Diffuse Large B-cell Lymphoma (DLBCL) and Refractory Diffuse Large B-Cell Lymphoma, sponsored by Andrés José Maria Ferreri. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Andrés José Maria Ferreri · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy — 31 open to participants now, 51 under way, 12 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Italy.
Among the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy, this one is the 12th largest by enrollment of the 22 observational ones that give a count, is one of 6 that started in 2025, is one of 22 observational ones, reaches primary completion later than 17 of the 50 other live ones, and was the 160th registered.
1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →31 of the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy are open now. Recruiting first, the newest first:
Taiho Oncology, Inc. · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, Australia and 9 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 13 more countries
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, France and 5 more countries
Ages 18+
Incyte Corporation · Sites in Italy, United States, Australia and 2 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
166 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 75 · Phase 3 41
First in 1994; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is close to the median of 150 across 186 observational studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 124 across the 143 interventional studies, 163 across the 22 observational. Of the 101 that completed or were terminated, 51 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 166 have an industry lead sponsor. The 10 most frequent:
Andrés José Maria Ferreri is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Andrés José Maria Ferreri has 2 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
15 of the studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04442022Phase 3Karyopharm Therapeutics IncA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | 2026-12 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05139017Phase 3Merck Sharp & Dohme LLCA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | 2027-09-24 |
| NCT07393204Andrés José Maria FerreriItalian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL | 2026-12-10 |
Add all 15 to your calendar (.ics) → With an account.
Among the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study describes the effectiveness of epcoritamab outside the clinical trial setting in pts with DLBCL relapsed or refractory after 2 or more previous lines of therapy
The study is expected to include approximately 150 patients. Patients registered in the Cnn program of epcoritamab (between February 19, 2024 and September 25, 2024) that received at least 1 dose of this antibody.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients registered in the Cnn program of epcoritamab (between February 19, 2024 and September 25, 2024) that received at least 1 dose of this antibody.
Overall Response Rate (ORR)
Overall Response Rate (ORR), defined as the best objective response achieved during or after treatment with epcoritamab, according to Lugano Criteria
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Adverse Event according to CTCAE v5.0
rate and severity of AEs (Adverse Event), AESIs (adverse events of special interest) and SAEs (Serious Adverse Event) according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0)
Time frame: through study completion, an average of 1 year
Incidence and Severity of Cytokine Release Syndrome (CRS)
Incidence and Severity of Cytokine Release Syndrome (CRS) according to ASTCT CRS grading criteria
Time frame: through study completion, an average of 1 year
Incidence and Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
ICANS graded according to ASTCT ICANS grading criteria (ICE score)
Time frame: through study completion, an average of 1 year
Complete Response rate
CR rate defined as the proportion of patients with CR, according to Lugano Criteria at 1, 2, 3, 6, 9 and 12 months since treatment start
Time frame: through study completion, an average of 1 year
Duration of Response
DoR is defined as the time from the first documentation of response (CR or PR) to the date of PD or death, whichever occurs earlier.
Time frame: through study completion, an average of 1 year
Duration of Complete Response
DoCR is defined as the time from the first documentation of CR to the date of PD or death, whichever occurs earlier.
Time frame: through study completion, an average of 1 year
Progression Free Survival
PFS is defined as the time from the start of the treatment to first documented PD or death due to any cause, whichever occurs earlier.
Time frame: through study completion, an average of 1 year
Overall Survival
OS is defined as the time from the start of epcoritamab treatment to death
Time frame: through study completion, an average of 1 year
Time To Next Treatment
TTNT is defined as duration from treatment initiation to the start of new anti-lymphoma therapy or death due to PD, whichever occurs earlier
Time frame: through study completion, an average of 1 year
Duration of Treatment
Duration of Treatment (DoT) is defined as the time from the start of the treatment to discontinuation or death due to any cause, whichever occurs earlier.
Time frame: through study completion, an average of 1 year
Health Care Resource Utilization (HCRU)
Health Care Resource Utilization (HCRU) as number and duration of unplanned hospitalizations during treatment and follow-up, number of hematological visits, load of diagnostic exams
Time frame: through study completion, an average of 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large B-Cell, Diffuse →
Andrés José Maria Ferreri